Michael Webb

Research in the group is focussed on creating new methods to precisely engineer proteins. O These methods are then applied to challenges across engineering biology including precision formation of biopharmaceuticals such as antibody-drug conjugates and vaccines, and the reengineering of cells. Current major projects include IMProGlyco, an EIC-funded project, to reprogramme cellular glycosylation and ACROPATH, a MRC-AMED-funded project to develop artificial cells as reporters for pathogens.